Home › Chronic Inflammatory Demyelinating Polyradiculoneuropathy › Ohio › Cleveland
Chronic Inflammatory Demyelinating Polyradiculoneuropathy clinical trials in Cleveland, OH
4 studies for Chronic Inflammatory Demyelinating Polyradiculoneuropathy are looking for participants at sites in and around Cleveland (within about 30 miles). Open a study to see who can join and how to contact the study team.
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RecruitingPhase 2/3
- Cleveland Clinic Main Campus, Cleveland
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RecruitingPhase 3
- University Hospitals Cleveland Medical Center- Site Number : 8400033, Cleveland
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
RecruitingPhase 1
- TG Therapeutics Investigational Trial Site, Cleveland
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
RecruitingPhase 3
- Cleveland Clinic, Cleveland
Chronic Inflammatory Demyelinating Polyradiculoneuropathy trials in other cities
- New York City, NY7 studies
- Houston, TX6 studies
- Miami, FL6 studies
- Indio, CA5 studies
- Philadelphia, PA5 studies
- Kansas City, KS5 studies
- St. Louis, MO5 studies
- New Haven, CT5 studies
- Washington, DC4 studies
- Birmingham, AL4 studies
- Tampa, FL4 studies
- Milwaukee, WI4 studies
Other studies in Cleveland
- Non-Small Cell Lung Cancer43 studies
- Cancer (all types)36 studies
- Breast Cancer35 studies
- Prostate Cancer34 studies
- Heart Failure33 studies
- Metastatic Cancer30 studies
- Ovarian Cancer28 studies
- Lung Cancer26 studies
- Colorectal Cancer24 studies
- Cardiovascular Disease22 studies
- Endometrial Cancer21 studies
- Acute Myeloid Leukemia20 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.